NasdaqGS - Delayed Quote • USD
Sangamo Therapeutics, Inc. (SGMO)
At close: 4:00 PM EDT
After hours: 4:54 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 8 |
| Avg. Estimate | -0.21 | -0.14 | -0.5 | -0.27 |
| Low Estimate | -0.27 | -0.21 | -0.77 | -0.64 |
| High Estimate | -0.1 | -0.08 | -0.23 | 0.28 |
| Year Ago EPS | 0.12 | -0.66 | -1.48 | -0.5 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 8 |
| Avg. Estimate | 6.65M | 8.24M | 45.88M | 79.01M |
| Low Estimate | 2M | 2M | 13.8M | 26.4M |
| High Estimate | 11.3M | 17.8M | 95M | 229M |
| Year Ago Sales | 157.96M | 14.83M | 176.23M | 45.88M |
| Sales Growth (year/est) | -95.80% | -44.40% | -74.00% | 72.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.34 | -0.32 | -0.26 |
| EPS Actual | 0.12 | -0.66 | -0.59 | -0.34 |
| Difference | 0.45 | -0.32 | -0.27 | -0.08 |
| Surprise % | 136.40% | -94.10% | -84.40% | -30.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.21 | -0.14 | -0.5 | -0.27 |
| 7 Days Ago | -0.21 | -0.14 | -0.5 | -0.27 |
| 30 Days Ago | -0.21 | -0.14 | -0.54 | -0.31 |
| 60 Days Ago | -0.11 | -0.1 | -0.48 | -0.48 |
| 90 Days Ago | -0.11 | -0.1 | -0.48 | -0.48 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SGMO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -275.00% | -- | -- | 1.60% |
| Next Qtr. | 78.80% | -- | -- | 10.50% |
| Current Year | 66.20% | -- | -- | 5.20% |
| Next Year | 46.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -17.90% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/14/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/19/2024 |
Related Tickers
ADAP Adaptimmune Therapeutics plc
0.9767
+8.72%
RIGL Rigel Pharmaceuticals, Inc.
1.0800
+2.86%
KPTI Karyopharm Therapeutics Inc.
1.1700
-8.59%
TSBX Turnstone Biologics Corp.
2.6200
-3.32%
MCRB Seres Therapeutics, Inc.
0.5599
-4.16%
HOOK HOOKIPA Pharma Inc.
0.7330
-4.17%
AFMD Affimed N.V.
5.15
+1.58%
DTIL Precision BioSciences, Inc.
9.74
-9.14%
MREO Mereo BioPharma Group plc
2.6400
-0.38%
QURE uniQure N.V.
4.6700
-0.85%